AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16364555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15291656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 11115082 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ATRA therapy
Number of subjects: 41
Study 11115082 — intervention group
Group type: COMPARATOR
Intervention: Control group (atenolol, hydrallazine, or methyldopa)
Number of subjects: 41
Study 8824965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200-800 mg daily, mostly 400 mg)
Number of subjects: 30
Study 1361311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 micrograms/kg DMED
Number of subjects: 37
Study 1361311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg DMED
Number of subjects: 37
Study 1361311 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg DMED
Number of subjects: 37
Study 1361311 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms/kg DMED
Number of subjects: 37
Study 1361311 — intervention group
Group type: COMPARATOR
Intervention: 0 micrograms/kg DMED (Placebo)
Number of subjects: 37
Study 6429693 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine administered IV (12.5 mg)
Number of subjects: 12
Study 6429693 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine administered orally (50 mg) after overnight fast
Number of subjects: 12
Study 6429693 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine administered orally (50 mg) 30 min after eating a standardized breakfast
Number of subjects: 12
Study 31545017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential peeling with 70% GA followed by 20% SA biweekly for three months
Number of subjects: 45
Study 31545017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential peeling and doxycycline PO100 mg BD for 1 month followed by 100 OD for 2 months
Number of subjects: 45
Study 31545017 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline
Number of subjects: 45
Study 29678158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion at 0.5 μg/kg/h from induction of anaesthesia to extubation (Group D)
Number of subjects: 60
Study 29678158 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (Group C)
Number of subjects: 60
Study 29194303 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 0
Study 26023230 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control) at 30% maximal voluntary contraction (MVC)
Number of subjects: 20
Study 26023230 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS inhibition in young adults
Number of subjects: 20
Study 24158154 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use
Number of subjects: 157
Study 24158154 — intervention group
Group type: EXPERIMENTAL
Intervention: Being Black
Number of subjects: 157
Study 24158154 — intervention group
Group type: EXPERIMENTAL
Intervention: Living on the streets
Number of subjects: 157
Study 24158154 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being part of a close family in childhood
Number of subjects: 157
Study 24158154 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 157
Study 21393318 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion about discipline with physician
Number of subjects: 259
Study 21393318 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the multimedia program
Number of subjects: 259
Study 21393318 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the multimedia program and discussion with physician
Number of subjects: 259
Study 21393318 — intervention group
Group type: COMPARATOR
Intervention: No discussion and no multimedia program
Number of subjects: 259
Study 18310199 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of live attenuated influenza vaccine with measles‐mumps‐rubella vaccine and varicella vaccine
Number of subjects: 1245
Study 18310199 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of live attenuated influenza vaccine
Number of subjects: 1245
Study 16699858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued lamivudine therapy (group A)
Number of subjects: 74
Study 16699858 — intervention group
Group type: COMPARATOR
Intervention: Discontinued lamivudine therapy (group B)
Number of subjects: 74
Study 16699858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 12721263 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 3560
Study 12721263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized Trials
Number of subjects: 3560
Study 10634958 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 16‐135‐1 (Prime & Bond(R) 2.1)
Number of subjects: 80
Study 10634958 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 17‐17‐1 (Dyract Adhesive(R) PSA)
Number of subjects: 80
Study 9033712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiconazole cream (1%) applied once daily
Number of subjects: 79
Study 9033712 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole cream (2%) applied once daily
Number of subjects: 79
Study 9033712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiconazole cream (1%)
Number of subjects: 79
Study 9033712 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole cream (2%)
Number of subjects: 79
Study 1482251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmomanometer, by a nurse, on supine position since 10 min, on the third day of hospitalization
Number of subjects: 64
Study 1482251 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic device (Dinamap), on supine position, every 5 min, during 30 min
Number of subjects: 64
Study 1482251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure (Spacelab 90202 every 15 min between 8 a.m. and 8 p.m.)
Number of subjects: 64
Study 1482251 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 64
Study 6094103 — intervention group
Group type: EXPERIMENTAL
Intervention: Suloctidil (200 mg 3-times daily)
Number of subjects: 23
Study 6094103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3884691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 496
Study 3884691 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 496
Study 3884691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction and weight reduction
Number of subjects: 496
Study 31332524 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based behavioral parent training
Number of subjects: 73
Study 28185774 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic focus (HF)
Number of subjects: 206
Study 28185774 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligation (CL)
Number of subjects: 206
Study 27519616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision (ME) alone
Number of subjects: 472
Study 27519616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision (ME) with lateral lymph node dissection (LLND)
Number of subjects: 472
Study 24913488 — intervention group
Group type: EXPERIMENTAL
Intervention: Visibility Enhancement System (VES) with two configurations: two continuous red lines or a series of red crosses
Number of subjects: 30
Study 24913488 — intervention group
Group type: EXPERIMENTAL
Intervention: Visibility Enhancement System (VES)
Number of subjects: 30
Study 24913488 — intervention group
Group type: COMPARATOR
Intervention: No VES (control condition)
Number of subjects: 30
Study 23990709 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of candesartan cilexetil 16 mg
Number of subjects: 24
Study 20501356 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg alendronate + 500 mg calcium
Number of subjects: 16
Study 20501356 — intervention group
Group type: COMPARATOR
Intervention: 500 mg calcium only
Number of subjects: 16
Study 18769826 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based sedation (group P)
Number of subjects: 40
Study 18769826 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 40
Study 16899486 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning process with two CD-ROMs containing digital images of 30 cases for diagnosis.
Number of subjects: 8
Study 16899486 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning process with two CD-ROMs containing digital images of 30 cases for diagnosis after selected background reading.
Number of subjects: 8
Study 14504773 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home mental health care
Number of subjects: 83
Study 10693901 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Disability Questionnaire (SDQ)
Number of subjects: 180
Study 10693901 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise therapy
Number of subjects: 180
Study 8787882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 150
Study 8787882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 150
Study 1522792 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated reminders for influenza vaccination
Number of subjects: 4555
Study 1522792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 4555
Study 6315261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonovine maleate administration
Number of subjects: 14
Study 6315261 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor testing
Number of subjects: 14
Study 6315261 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 14
Study 6315261 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion after beta-blockade
Number of subjects: 14
Study 6315261 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine infusion at the highest tolerated dose
Number of subjects: 14
Study 31832001 — intervention group
Group type: EXPERIMENTAL
Intervention: LB100
Number of subjects: 0
Study 28159505 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health (DH) with sensor-enabled medicines for 4 or 12 weeks
Number of subjects: 57
Study 28159505 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 57
Study 28159505 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health (DH) with sensor-enabled medicines
Number of subjects: 57
Study 26488677 — intervention group
Group type: COMPARATOR
Intervention: Site-rated Hamilton Anxiety Scale (HAM-A)
Number of subjects: 122
Study 26488677 — intervention group
Group type: COMPARATOR
Intervention: Remote centralized raters' assessment of HAM-A
Number of subjects: 122
Study 23936148 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid/vitamin B12 (± B6)
Number of subjects: 102
Study 23936148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (± B6)
Number of subjects: 102
Study 20693247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trial rehabilitation followed by surgery or medical care
Number of subjects: 1218
Study 19185817 — intervention group
Group type: EXPERIMENTAL
Intervention: MuViCure (audiovisual stimulation)
Number of subjects: 55
Study 19185817 — intervention group
Group type: EXPERIMENTAL
Intervention: MusiCure (audio stimulation)
Number of subjects: 55
Study 19185817 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 55
Study 16422138 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic breathing and meditation intervention
Number of subjects: 47
Study 16422138 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 47
Study 14960519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-colonic chromoscopy using 0.5% indigo carmine
Number of subjects: 260
Study 14960519 — intervention group
Group type: COMPARATOR
Intervention: Targeted chromoscopy (control group)
Number of subjects: 260
Study 11478588 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 18
Study 11478588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9610350 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of the common femoral Doppler waveform
Number of subjects: 73
Study 9610350 — intervention group
Group type: EXPERIMENTAL
Intervention: Common femoral waveform analysis
Number of subjects: 73
Study 8047814 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day oral isosorbide-5-mononitrate retard
Number of subjects: 76
Study 8047814 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 76
Study 3054777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 136
Study 3054777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 5071699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 37
Study 5071699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fusidate
Number of subjects: 37
Study 5071699 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 31778222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting a systolic blood pressure (SBP) of 120 mm Hg
Number of subjects: 2313
Study 31778222 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy targeting a systolic blood pressure (SBP) of 140 mm Hg
Number of subjects: 2313
Study 31778222 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 75 years and older
Number of subjects: 2313
Study 31778222 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants younger than 75 years
Number of subjects: 2313
Study 31778222 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified by age
Number of subjects: 2313
Study 31344287 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTRC Shoulder Injury Prevention Programme
Number of subjects: 44
Study 31344287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 28209506 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection plus splinting
Number of subjects: 52
Study 28209506 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection alone
Number of subjects: 52
Study 25151027 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa treatment for 6 months (Group 2A)
Number of subjects: 159
Study 25151027 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete laparoscopic excision of DIE (Group 1A)
Number of subjects: 159
Study 25151027 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 1A)
Number of subjects: 159
Study 25151027 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa treatment for 6 months (Group 2B)
Number of subjects: 159
Study 25151027 — intervention group
Group type: COMPARATOR
Intervention: Incomplete surgical treatment (Group 1B)
Number of subjects: 159
Study 23531019 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 600
Study 23531019 — intervention group
Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 600
Study 21665462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (FOLFIRI)
Number of subjects: 89
Study 21665462 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent irinotecan
Number of subjects: 89
Study 19307374 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (1 g intravenously every 6 hours)
Number of subjects: 36
Study 19307374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus oral P1A recombinant beta-lactamase (8.2 mg every 6 hours)
Number of subjects: 36
Study 19307374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral P1A recombinant beta-lactamase (8.2 mg every 6 hours)
Number of subjects: 36
Study 16540279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural training programme (exercise treatment plus cognitive-behavioural training)
Number of subjects: 47
Study 16540279 — intervention group
Group type: COMPARATOR
Intervention: Exercise treatment only (control group)
Number of subjects: 47
Study 15228184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adalimumab (1 mg/kg)
Number of subjects: 54
Study 15228184 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab (1 mg/kg)
Number of subjects: 54
Study 15228184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10932067 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu mAb‐E25
Number of subjects: 251
Study 10932067 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study 9118763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro (0.15 U/kg)
Number of subjects: 12
Study 9118763 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 12
Study 8511505 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PEN), 2.4 million units twice daily for up to 14 weeks
Number of subjects: 170
Study 8511505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 170
Study 8511505 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PEN)
Number of subjects: 170
Study 3318454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (100 mg, three times daily)
Number of subjects: 240
Study 3318454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 30333494 — intervention group
Group type: EXPERIMENTAL
Intervention: SPINK1 targeting in the damaged TME
Number of subjects: 0
Study 26496680 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropulse vibration device used for 20 minutes daily
Number of subjects: 58
Study 26496680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no micropulse vibration device)
Number of subjects: 58
Study 25152506 — intervention group
Group type: EXPERIMENTAL
Intervention: Public-private collaboration involving joint community clinics and public health department nurses aiding in delivery at practices
Number of subjects: 8
Study 25152506 — intervention group
Group type: COMPARATOR
Intervention: Usual care without public health department involvement
Number of subjects: 8
Study 22541758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiology care
Number of subjects: 70
Study 22541758 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study 20419161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (oAC)
Number of subjects: 52
Study 20419161 — intervention group
Group type: COMPARATOR
Intervention: Oral activated charcoal (oAC) with artesunate (AS)
Number of subjects: 52
Study 17311303 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg
Number of subjects: 327
Study 17311303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 16870053 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 348
Study 12603234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Change system (Manual intervention) with self-help workbook and three questionnaires at 3-month intervals
Number of subjects: 2471
Study 12603234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Change system plus three telephone calls (Phone intervention)
Number of subjects: 2471
Study 12603234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Change system plus three visits to the practice nurse (Nurse intervention)
Number of subjects: 2471
Study 12603234 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard self-help literature
Number of subjects: 2471
Study 11374852 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in high-density lipoprotein cholesterol (HDL-C) by 6%
Number of subjects: 0
Study 11374852 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in triglyceride levels by 31%
Number of subjects: 0
Study 11374852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in triglycerides in patients with baseline triglycerides >200 mg/dL (from Bezafibrate Infarction Prevention trial)
Number of subjects: 0
Study 8795482 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting with standardised anticoagulation regimen (intravenous heparin, oral vitamin K antagonist, 100 mg aspirin twice daily)
Number of subjects: 30
Study 8795482 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting with standardised anticoagulation regimen
Number of subjects: 30
Study 8795482 — intervention group
Group type: COMPARATOR
Intervention: Control group (elective coronary balloon angioplasty)
Number of subjects: 30
Study 7745993 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2, 1 x 106 I.U./day)
Number of subjects: 75
Study 7745993 — intervention group
Group type: COMPARATOR
Intervention: Vaccine only
Number of subjects: 75
Study 2950340 — intervention group
Group type: EXPERIMENTAL
Intervention: Manufacturer-developed gloved procedure
Number of subjects: 40
Study 2950340 — intervention group
Group type: COMPARATOR
Intervention: Nongloved procedure developed by clinic nursing staff
Number of subjects: 40
Study 31422713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10/20 mg
Number of subjects: 529
Study 31422713 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 529
Study 31422713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 29689081 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-hour mindfulness course over seven weeks with booster sessions twice yearly
Number of subjects: 288
Study 29689081 — intervention group
Group type: COMPARATOR
Intervention: Normal study curricula
Number of subjects: 288
Study 26945156 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF6001 (inhaled PDE4 inhibitor)
Number of subjects: 100
Study 26945156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of CHF6001
Number of subjects: 100
Study 26945156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic/pharmacodynamic analysis of CHF6001
Number of subjects: 100
Study 26945156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study 26461847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combined androgen blockade (CAB) for ≥ 6 months
Number of subjects: 431